Prostatype Genomics AB (PROGEN) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.234x

Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has a cash flow conversion efficiency ratio of -0.234x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.54 Million ≈ $-918.99K USD) by net assets (Skr36.48 Million ≈ $3.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Prostatype Genomics AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Prostatype Genomics AB - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Prostatype Genomics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Prostatype Genomics AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Prostatype Genomics AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Reliance Global Group Inc NASDAQ:RELI	-0.077x
Avalon GloboCare Corp. NASDAQ:ALBT	-0.264x
DelphX Capital Markets Inc V:DELX	0.197x
Audeara Ltd AU:AUA	0.024x
Matinas BioPharma Holdings Inc NYSE MKT:MTNB	-0.530x
Nordic Asia Investment Group 1987 AB Series B ST:NAIG-B	-0.087x
Preecha Group Public Company Limited BK:PRECHA	-0.044x
Riedel Resources Ltd AU:RIE	-0.041x

Annual Cash Flow Conversion Efficiency for Prostatype Genomics AB (2016–2024)

The table below shows the annual cash flow conversion efficiency of Prostatype Genomics AB from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Prostatype Genomics AB.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr33.47 Million ≈ $3.60 Million	Skr-44.71 Million ≈ $-4.81 Million	-1.336x	-13.12%
2023-12-31	Skr24.67 Million ≈ $2.66 Million	Skr-29.14 Million ≈ $-3.14 Million	-1.181x	-11.52%
2022-12-31	Skr26.15 Million ≈ $2.81 Million	Skr-27.69 Million ≈ $-2.98 Million	-1.059x	-136.49%
2021-12-31	Skr35.91 Million ≈ $3.86 Million	Skr-16.08 Million ≈ $-1.73 Million	-0.448x	+13.89%
2020-12-31	Skr28.29 Million ≈ $3.04 Million	Skr-14.71 Million ≈ $-1.58 Million	-0.520x	+53.85%
2018-12-31	Skr8.55 Million ≈ $919.74K	Skr-9.63 Million ≈ $-1.04 Million	-1.127x	-22.82%
2017-12-31	Skr6.22 Million ≈ $669.69K	Skr-5.71 Million ≈ $-614.46K	-0.918x	-42.21%
2016-12-31	Skr14.93 Million ≈ $1.61 Million	Skr-9.63 Million ≈ $-1.04 Million	-0.645x	--

About Prostatype Genomics AB

ST:PROGEN Sweden Diagnostics & Research

Market Cap

$4.09 Million

Skr38.00 Million SEK

Market Cap Rank

#28928 Global

#655 in Sweden

Share Price

Skr0.64

Change (1 day)

+28.40%

52-Week Range

Skr0.30 - Skr1.95

All Time High

Skr1803.71